Publication: A Plain Language Summary on the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the MSBase Registry
| dc.authorwosid | Laureys, Guy/Aah-6369-2019 | |
| dc.authorwosid | Kuhle, Jens/Age-3474-2022 | |
| dc.authorwosid | Soysal, Aysun/Aax-7696-2021 | |
| dc.authorwosid | Horakova, Dana/D-4649-2011 | |
| dc.authorwosid | Terzi̇, Murat/Aaa-1284-2021 | |
| dc.authorwosid | Van Pesch, Vincent/Aak-9506-2020 | |
| dc.contributor.author | Spelman, Tim | |
| dc.contributor.author | Ozakbas, Serkan | |
| dc.contributor.author | Alroughani, Raed | |
| dc.contributor.author | Terzi, Murat | |
| dc.contributor.author | Hodgkinson, Suzanne | |
| dc.contributor.author | Laureys, Guy | |
| dc.contributor.author | MSBase Study Grp | |
| dc.contributor.authorID | Kuhle, Jens/0000-0002-6963-8892 | |
| dc.contributor.authorID | Sánchez Menoyo, José Luis/0000-0003-2634-8294 | |
| dc.contributor.authorID | Al Asmi, Abdullah/0000-0002-2851-8157 | |
| dc.contributor.authorID | Van Pesch, Vincent/0000-0003-2885-9004 | |
| dc.date.accessioned | 2025-12-11T01:33:54Z | |
| dc.date.issued | 2023 | |
| dc.department | Ondokuz Mayıs Üniversitesi | en_US |
| dc.department-temp | [Spelman, Tim; Butzkueven, Helmut] MSBase Fdn, Melbourne, Australia; [Ozakbas, Serkan] Dokuz Eylul Univ, Izmir, Turkiye; [Alroughani, Raed] Amiri Hosp, Sharq, Kuwait; [Terzi, Murat] 19 Mayis Univ, Dept Neurol, Samsun, Turkiye; [Hodgkinson, Suzanne] Liverpool Hosp, Sydney, Australia; [Laureys, Guy] Univ Hosp Ghent, Ghent, Belgium; [Kalincik, Tomas] Royal Melbourne Hosp, MS Ctr, Dept Neurol, Melbourne, Australia; [Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Australia; [Butzkueven, Helmut] Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Australia; [Yamout, Bassem] Harley St Med Ctr, Neurol Inst, Abu Dhabi, U Arab Emirates; [Yamout, Bassem] Amer Univ Beirut, Med Ctr, Beirut, Lebanon; [Lechner-Scott, Jeannette] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, Australia; [Lechner-Scott, Jeannette] Hunter New England Hlth, Dept Neurol, John Hunter Hosp, Newcastle, Australia; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkiye; [Kuhle, Jens] Univ Hosp Basel, Multiple Sclerosis Ctr, Dept Head Spine & Neurosurg, Neurol, Basel, Switzerland; [Kuhle, Jens] Univ Hosp Basel, Multiple Sclerosis Ctr, Dept Biomed, Neurol, Basel, Switzerland; [Kuhle, Jens] Univ Hosp Basel, Multiple Sclerosis Ctr, Dept Clin Res, Neurol, Basel, Switzerland; [Kuhle, Jens] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci RC2NB, Basel, Switzerland; [Kuhle, Jens] Univ Basel, Basel, Switzerland; [Sanchez-Menoyo, Jose Luis] Galdakao Usansolo Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Dept Neurol, Osakidetza Basque Hlth Serv, Galdakao, Spain; [Morgado, Yolanda Blanco] Hosp Clin Barcelona, Ctr Neuroimmunol, Serv Neurol, Barcelona, Spain; [Spitaleri, Daniele L. A.] Azienda Osped Rilievo Nazl San Giuseppe Moscati Av, Avellino, Italy; [van Pesch, Vincent] UCLouvain, Clin Univ St Luc, Brussels, Belgium; [Horakova, Dana] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Horakova, Dana] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Horakova, Dana] Gen Univ Hosp, Prague, Czech Republic; [Ampapa, Radek] Nemocnice Jihlava, Jihlava, Czech Republic; [Patti, Francesco] GF Ingrassia, Dept Med & Surg Sci & Adv Technol, Catania, Italy; [Macdonell, Richard] Austin Hlth, Dept Neurol, Melbourne, Australia; [Al-Asmi, Abdullah] SQU, Coll Med & Hlth Sci, Dept Med, Neurol Unit, Al Khoud, Oman; [Al-Asmi, Abdullah] SQU, Sultan Qaboos Univ Hosp, Al Khoud, Oman; [Gerlach, Oliver] Zuyderland Med Ctr, Acad MS Ctr Zuyderland, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Oh, Jiwon] Univ Toronto, St Michaels Hosp, Div Neurol, Toronto, ON, Canada; [Altintas, Ayse] Koc Univ, Sch Med, Istanbul, Turkiye; [Altintas, Ayse] Koc Univ, Res Ctr Translat Med KUTTAM, Istanbul, Turkiye; [Tundia, Namita; Wong, Schiffon L.] EMD Serono Res & Dev Inst Inc, Billerica, MA USA | en_US |
| dc.description | Kuhle, Jens/0000-0002-6963-8892; Sánchez Menoyo, José Luis/0000-0003-2634-8294; Al Asmi, Abdullah/0000-0002-2851-8157; Van Pesch, Vincent/0000-0003-2885-9004; | en_US |
| dc.description.abstract | What is this summary about?Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad((R))) compared with other oral treatments.What were the results?Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.What do the results mean?The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS. | en_US |
| dc.description.woscitationindex | Emerging Sources Citation Index | |
| dc.identifier.doi | 10.2217/nmt-2023-0005 | |
| dc.identifier.endpage | 221 | en_US |
| dc.identifier.issn | 1758-2024 | |
| dc.identifier.issn | 1758-2032 | |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.pmid | 37287269 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | 215 | en_US |
| dc.identifier.uri | https://doi.org/10.2217/nmt-2023-0005 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/44642 | |
| dc.identifier.volume | 13 | en_US |
| dc.identifier.wos | WOS:001025040700002 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis Ltd | en_US |
| dc.relation.ispartof | Neurodegenerative Disease Management | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Cladribine Tablets | en_US |
| dc.subject | Dimethyl Fumarate (Tecfidera(& Reg | en_US |
| dc.subject | )) | en_US |
| dc.subject | Fingolimod (Gilenya(& Reg | en_US |
| dc.subject | )) | en_US |
| dc.subject | Lay Summary | en_US |
| dc.subject | Multiple Sclerosis | en_US |
| dc.subject | Relapses | en_US |
| dc.subject | Teriflunomide (Aubagio(& Reg | en_US |
| dc.subject | )) | en_US |
| dc.subject | Treatment Options | en_US |
| dc.title | A Plain Language Summary on the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the MSBase Registry | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication |
